Novavax
NVAX
389 hedge funds and large institutions have $7.7B invested in Novavax in 2021 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 100 increasing their positions, 140 reducing their positions, and 58 closing their positions.
79% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 58
78% more capital invested
Capital invested by funds: $4.34B → $7.7B (+$3.37B)
12% more funds holding
Funds holding: 347 → 389 (+42)
12% more call options, than puts
Call options by funds: $893M | Put options by funds: $797M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3.41% less ownership
Funds ownership: 60.99% → 57.58% (-3.4%)
29% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 140
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$606M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$211M |
| 3 |
Renaissance Technologies
New York
|
+$134M |
| 4 |
CG
Carmignac Gestion
Paris,
France
|
+$105M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$157M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$148M |
| 3 |
PA
Perceptive Advisors
New York
|
-$116M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$113M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$71M |
NVAX Hedge Fund Activity: Q1 2021 in Review
389 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2021, worth a combined $7.7B — up 78% from $4.34B a quarter earlier.
Buyers outnumbered sellers: 104 funds opened new NVAX positions and 58 closed out — a net gain of 46 holders — while 100 added to existing stakes and 140 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $606M. The largest seller was RA Capital Management, cutting an estimated $157M.
- 389 institutional investors held Novavax (NVAX) as of Q1 2021, up from 347 in Q4 2020.
- Funds reported $7.7B of Novavax stock for Q1 2021, up 78% quarter-over-quarter.
- 104 funds opened new Novavax positions in Q1 2021 and 58 closed out, a net change of +46 holders.
- The largest Novavax buyer in Q1 2021 was Fidelity Investments, an estimated $606M added.
- The largest Novavax seller in Q1 2021 was RA Capital Management, an estimated $157M sold.
Based on aggregated 13F filings for Q1 2021.